middle.news
Opthea Halts Sozinibercept, Cuts Staff 85%, Cash Drops to $48.4M Amid Funding Talks
8:45am on Wednesday 30th of July, 2025 AEST
•
Biotechnology
Read Story
Opthea Halts Sozinibercept, Cuts Staff 85%, Cash Drops to $48.4M Amid Funding Talks
8:45am on Wednesday 30th of July, 2025 AEST
Key Points
Discontinuation of sozinibercept development following failed Phase 3 trials
Staff reduced by approximately 85%, board halved
Operational spending on ShORe and COAST trials completed
Cash reserves fell from US$101.4m to US$48.4m in Q4 FY25
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE